Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention.
While more research will be necessary, the study’s lead author Nima Sharifi, MD, said the findings from the team’s analysis of nearly 700 patients may have clinical implications for diagnosing and preventing lethal prostate cancer.
Nima Sharifi, MD
“We found that men with higher levels of certain diet-related molecules are more likely to develop aggressive prostate cancer,” said Dr. Sharifi, Director of Cleveland Clinic’s Genitourinary Malignancies Research Center. “As we continue our research in this area, our hope is that one day these molecules can be used as early biomarkers of prostate cancer and help identify patients who can modify their disease risk by making dietary and lifestyle changes.”
In this study, Dr. Sharifi and his collaborators analyzed data from patients previously enrolled in the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. They studied baseline levels of certain dietary nutrients and metabolites (byproducts produced when a substance is broken down in the gut) found in patients’ blood serum prior to prostate cancer diagnosis. They compared serum levels between healthy patients and those who later received a prostate cancer diagnosis and died from the disease.
Role of PAGln
The researchers found that men with elevated levels of a metabolite called phenylacetylglutamine (PAGln) were approximately two to three times more likely to be diagnosed with lethal prostate cancer. This metabolite is produced when microbes in the gut break down phenylalanine, an amino acid found in many plant- and animal-based protein sources like meat, beans, and soy.
In addition to PAGln, researchers also discovered that elevated levels of two nutrients abundant in animal products, including red meat, egg yolks, and high-fat dairy products—choline and betaine—were also linked with an increased risk of aggressive prostate cancer. While these nutrients and gut metabolites have been studied previously in heart disease and stroke, this is the first time that gut microbiome metabolites have been studied clinically in relation to prostate cancer outcomes.
Study coauthor Stanley Hazen, MD, PhD, was the first to identify PAGln’s association with increased cardiovascular disease risk. The findings were published in 2020 in the journal Cell.
“Interestingly, we found that PAGln binds to the same receptors as beta blockers, which are drugs commonly prescribed to help lower blood pressure and subsequent risk of cardiac events,” said Dr. Hazen, Director of Cleveland Clinic’s Center for Microbiome & Human Health and Chair of Lerner Research Institute’s Department of Cardiovascular & Metabolic Sciences. “This suggests that part of beta blockers’ potent efficacy may be due to blocking the metabolite’s activity.”
“New insights are emerging from large-scale clinical datasets that show use of beta blockers is also associated with lower mortality due to prostate cancer,” said Dr. Sharifi, who is also a staff physician in the Lerner Research Institute’s Department of Cancer Biology. “We will continue to work together to investigate the possible mechanisms linking PAGln activity and prostate cancer disease processes in hopes of identifying new therapeutic targets for our patients.”
The research team also will continue to explore the reliability of using choline, betaine, and PAGln as biomarkers of aggressive prostate cancer, and how dietary interventions can be used to modulate their levels and reduce patients’ subsequent disease risk.
Disclosure: The research was supported by the National Cancer Institute and the National Heart, Lung, and Blood Institute, as well as the Prostate Cancer Foundation. For full disclosures of the study authors, visit cebp.aacrjournals.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.